Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| NB Network BioCompany profile Builds AI models trained on patient tissue and clinical data for disease diagnostics Builds AI models trained on patient tissue and clinical data for disease diagnostics | $50M | StrategicUndisclosed | Biotech | United States | Investors | |
| A AuraGxPCompany profile AI-native SaaS platform connecting quality, procurement and vendor management for life sciences AI-native SaaS platform connecting quality, procurement and vendor management for life sciences | Undisclosed | Seed | Biotech | United States | Investors Undisclosed | |
| C ComputomicsCompany profile Machine learning platform predicting crop variety performance for climate-smart breeding Machine learning platform predicting crop variety performance for climate-smart breeding | €6.3M | Series B | Biotech, Agritech | Germany | Investors | |
| A AbcuroCompany profile Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease. Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease. | $66M | Series DSeries C+ | Biotech | United States | Investors | |
| LT Develops neuro-metabolic therapeutics for schizophrenia and ALS | $30M | Series A | Biotech | United States | Investors | |
| G GamgeeCompany profile Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor. Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor. | $4M | Seed | Biotech | United States | Investors | |
| eH eubiOmic HealthCompany profile eubiOmic Health develops clinical nutrition for patients with a temporary ileostomy following rectal surgery. eubiOmic Health develops clinical nutrition for patients with a temporary ileostomy following rectal surgery. | €200K | First investment roundUndisclosed | Biotech | Spain | Investors | |
| R RasynCompany profile Rasyn gives chemists a chat interface to run real chemistry software tools on their own hardware. Rasyn gives chemists a chat interface to run real chemistry software tools on their own hardware. | Undisclosed | Seed | Biotech | United States | Investors | |
| KT Khartis TherapeuticsCompany profile Develops oral small molecule therapies for immunological and chronic diseases Develops oral small molecule therapies for immunological and chronic diseases | $50M | Series B | Biotech | United States | Investors | |
| BT Beyang TherapeuticsCompany profile AI-driven drug discovery company using its ExCEED molecular design platform AI-driven drug discovery company using its ExCEED molecular design platform | $30M | Series A | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.